HIV injections work better than tablets for young people
Young people living with HIV manage their condition better when their antiretroviral therapy is given by injections every eight weeks, rather than in the form of daily tablets,… read more.
Young people living with HIV manage their condition better when their antiretroviral therapy is given by injections every eight weeks, rather than in the form of daily tablets,… read more.
Zealand Pharma A/S announces the initiation of the global registrational Phase 3 Zupreme program, evaluating the efficacy and safety of once-weekly petrelintide versus placebo in people with overweight… read more.
Actinogen Medical is pleased to announce that following the final trial participant visit yesterday in the USA, the Company can now confirm that topline results for the XanaMIA… read more.
Where a patient undergoes heart surgery can significantly affect their risk of infection following the procedure, with some patients facing more than double the risk of others, according… read more.
Adults 65 and older with cognitive disorders such as dementia, are more likely to suffer negative effects from drugs that treat central nervous system conditions including anxiety, sleep… read more.
Johnson & Johnson announced positive topline results from the pivotal Phase 3 study evaluating CAPLYTA (lumateperone) for the treatment of manic episodes with or without mixed features in… read more.
Gossamer Bio, Inc. announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in September 2026 for seralutinib for the treatment… read more.
A total of 363,039 cataract surgeries performed in 12 European countries in 2024 have been recorded in the European Registry of Quality Outcomes for Cataract and Refractive Surgery… read more.
Redness and pain at the injection site, fever, fatigue or headaches: vaccines can cause side effects, but their frequency and severity vary considerably from person to person. Why?… read more.
Novo Nordisk announced topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly CagriSema (cagrilintide and semaglutide), an investigational product, and Novo’s next innovation… read more.
AstraZeneca’s fixed-dose triple-combination Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate or BGF (320/28.8/10μg)) has been approved in the European Union (EU) as a maintenance treatment for asthma in patients 12… read more.
Differences in how palliative care and oncology teams work together may help explain variation in end-of-life outcomes for patients with cancer, according to a multicentre qualitative study published… read more.